Reversal of Major Genotypic Tipranavir Mutations Under Long-Term Treatment with Tipranavir/Ritonavir Itself with Very Limited Optimized Background, During Deep Salvage Antiretroviral Therapy

Title: Reversal of Major Genotypic Tipranavir Mutations Under Long-Term Treatment with Tipranavir/Ritonavir Itself with Very Limited Optimized Background, During Deep Salvage Antiretroviral Therapy

Volume: 7 Issue: 3

Author(s): Sergio Sabbatani, Roberto Manfredi, Ciro Fulgaro and Isabella Bon

Affiliation:

Keywords: Antiretroviral therapy, tipranavir, genotypic mutations, reversal of key mutations, tipranavir mutation score, salvage antiretroviral therapy

Abstract: A reversal of key HIV protease mutations against tipranavir has been observed in a patient undergoing a late salvage antiretroviral therapy. Our patient initially introduced tipranavir/ritonavir in absence of an optimized background and novel drug classes, and nevertheless he experienced a virological-immunological benefit. Our report is a contribution to the present debate around the role of each single HIV protease mutation, and the validation of mutational “scores” (like the so-called tipranavir weighted score), to be applied to last-generation protease inhibitor compounds initially targeted on patients with limited, residual therapeutic options.

Cite this article as:

Sabbatani Sergio, Manfredi Roberto, Fulgaro Ciro and Bon Isabella, Reversal of Major Genotypic Tipranavir Mutations Under Long-Term Treatment with Tipranavir/Ritonavir Itself with Very Limited Optimized Background, During Deep Salvage Antiretroviral Therapy, Current HIV Research 2009; 7 (3) . https://dx.doi.org/10.2174/157016209788347994